Recurrent Disease Completed Phase 1 / 2 Trials for Tipifarnib (DB04960)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02210858Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersTreatment